Table 2.
Summary of vaccination and healthcare costs in the studiesj,k
| Vaccination cost | IPDa hospitalization | Non-invasive | |||||
|---|---|---|---|---|---|---|---|
| Author/Country | Currency base | Perspective | Administration cost | PPV23 | PCV13 | cost | hospitalization cost |
| Smith et al. 24/US | 2006 US $ | Societal | Not reported | $43b | $128b | $20,416 | $16,925 |
| Weycker et al. 25/US | 2010 US $ | Societal and Health care provider | $17 | $49 | $108 | $26,434 $32,795d | $15,564 |
| Smith et al. 26/US | 2006 US $ | Societal | Not reported | $43b | $128b | $20,416 | $16,925 |
| Smith et al. 27/US | 2006 US $ | Societal | Not reported | $43b | $128b | $20,416 | $16,925 |
| Cho et al. 28/US | 2009 US $ | Societal | $25 | $55.02 | $124.37 | $25,702-$79,193e | $18,380-$26,526e |
| Boccalini et al. 29/Italy | 2012 € | Health care provider | Not reported | €16 ($20.8) | €42.5 ($55.25) | €4068f-€19,114d ($5288.4f-$24848d) | €2680.85 ($3485.1) |
| Liguori et al. 30/Italy | Not reported | Health care provider | NA | Not reported | €42.5 ($55.25) | €3809 ($4951.7) | €3809 ($4951.7) |
| Rozenbaum et al. 32/Netherlands | 2010 € | Societal | Not reported | Not reported | €50 ($65) | €7105g, -€15,255d ($9236.5g-$19,831.5d) | €5194 ($6752.2) |
| Rozenbaum et al. 31/England | 2012 £ | Health care provider | £7.51 ($12.01) | Not reported | £56.61 ($90.576) | £825h-£8977i ($1320h-$14,363i) | £661 ($1057.6) |
| Pradas et al.33 /Spain | 2010 € | Health care provider | Not reported | Not reported | €49.91 ($64.88) (ex-factory ) | €4093c-€11,202d ($5320.9c-$14,562d) | €1983 ($2577.9) |
aIPD: Invasive pneumococcal disease.
bInclusive administration cost.
cCost of bacteremia.
dCost of meningitis.
eThe range for hospitalization among different immunocompromised conditions.
fCost of bacteremic pneumococcal pneumonia.
gCost of pneumococcal bacteremia with a focus.
hCost of short hospital stay.
iCost of long hospital stay.
jAll currencies were converted to US dollar based on €1=$1.3 and £1=$1.6.
kHealthcare costs are in the groups targeted as shown in Table 1.